OKYO OKYO Pharma Limited logo

OKYO OKYO Pharma Limited

Healthcare
$1.63-1.81%ClosedMarket Cap: $62.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-17.86

P/S

0.00

EV/EBITDA

-6.10

DCF Value

$-0.11

FCF Yield

-5.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

102.9%

ROA

-99.3%

ROIC

154.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$0.00$-2.6M$
Q4 null$0.00$-2.0M$
FY null$0.00$-4.7M$
Q2 null$0.00$-2.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-09-23

Trading Activity

Insider Trades

View All
Shah Keeren Rameshchandraofficer: CHIEF FINANCIAL OFFICER
SellFri May 22
Shah Keeren Rameshchandraofficer: CHIEF FINANCIAL OFFICER
SellFri May 22
Shah Keeren Rameshchandraofficer: CHIEF FINANCIAL OFFICER
SellFri May 22
Shah Keeren Rameshchandraofficer: CHIEF FINANCIAL OFFICER
SellFri May 22
Shah Keeren Rameshchandraofficer: CHIEF FINANCIAL OFFICER
SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

GB

Exchange

Beta

-0.05

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Peers